阿达木单抗加重顽固性皮肤结节病——一种矛盾的效应？病例报告。
Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
作者信息
Santos Guida, Sousa Lourdes Emerenciano, João Alexandre Miguel Bruno Lopes
机构信息
Centro Hospitalar de Lisboa Central, Santo António dos Capuchos Hospital, Dermatolovenereology Department, Lisbon.
Centro Hospitalar de Setúbal, São Bernardo Hospital, Setúbal, Portugal.
出版信息
An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):26-8. doi: 10.1590/abd1806-4841.20132487.
Abstract
The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.
摘要
由于肿瘤坏死因子-α（TNF-α）拮抗剂的广泛使用，其矛盾的不良反应已被频繁报道。在TNF-α阻断剂中，关于阿达木单抗用于皮肤结节病的报道很少，尽管所有报道都显示出良好效果。最近，已有使用各种TNF-α抑制剂后出现结节病发作的报道。据我们所知，本病例是首例描述用阿达木单抗治疗的结节病皮肤病变加重的病例。
相似文献
1
Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):26-8. doi: 10.1590/abd1806-4841.20132487.
2
A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.
J Am Acad Dermatol. 2013 May;68(5):765-73. doi: 10.1016/j.jaad.2012.10.056. Epub 2012 Dec 28.
3
Adalimumab for treatment of cutaneous sarcoidosis.
Arch Dermatol. 2006 Jan;142(1):17-9. doi: 10.1001/archderm.142.1.17.
4
Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Dermatology. 2009;219(1):59-62. doi: 10.1159/000221005. Epub 2009 May 25.
5
Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.
Am J Otolaryngol. 2013 May-Jun;34(3):268-72. doi: 10.1016/j.amjoto.2012.12.016. Epub 2013 Jan 26.
6
Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.
Rheumatol Int. 2012 Aug;32(8):2367-70. doi: 10.1007/s00296-011-1968-x. Epub 2011 Jun 5.
7
Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
Clin Respir J. 2012 Oct;6(4):238-47. doi: 10.1111/j.1752-699X.2011.00276.x. Epub 2012 Feb 13.
8
[Sarcoidosis after adalimumab treatment in inflammatory rheumatic diseases: a report of two cases and literature review].
Presse Med. 2015 Jan;44(1):4-10. doi: 10.1016/j.lpm.2014.06.028. Epub 2014 Dec 19.
9
Ulcerative cutaneous sarcoidosis responding to adalimumab.
J Am Acad Dermatol. 2005 Nov;53(5):917. doi: 10.1016/j.jaad.2005.02.023.
10
Successful treatment of lupus pernio with adalimumab.
Arch Dermatol. 2011 Nov;147(11):1332-3. doi: 10.1001/archdermatol.2011.307.
引用本文的文献
1
Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review.
Cureus. 2023 Sep 8;15(9):e44901. doi: 10.7759/cureus.44901. eCollection 2023 Sep.
2
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Biomedicines. 2021 Oct 15;9(10):1482. doi: 10.3390/biomedicines9101482.
3
Granulomatous Cutaneous Drug Eruptions: A Systematic Review.
Am J Clin Dermatol. 2021 Jan;22(1):39-53. doi: 10.1007/s40257-020-00566-4.
4
Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.
Intern Med. 2020 Aug 15;59(16):2015-2021. doi: 10.2169/internalmedicine.4275-19. Epub 2020 May 8.
5
Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa.
JAAD Case Rep. 2018 Jun 6;4(6):543-545. doi: 10.1016/j.jdcr.2018.03.007. eCollection 2018 Jul.
6
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
J Immunother Cancer. 2018 Feb 12;6(1):14. doi: 10.1186/s40425-018-0323-0.
7
Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature.
Ann Dermatol. 2017 Feb;29(1):74-78. doi: 10.5021/ad.2017.29.1.74. Epub 2017 Feb 3.
本文引用的文献
1
Successful treatment of lupus pernio with adalimumab.
Arch Dermatol. 2011 Nov;147(11):1332-3. doi: 10.1001/archdermatol.2011.307.
2
Disfiguring annular sarcoidosis improved by adalimumab.
Case Rep Dermatol. 2011 May;3(2):103-6. doi: 10.1159/000328796. Epub 2011 May 17.
3
[Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review].
Therapie. 2011 Mar-Apr;66(2):149-54. doi: 10.2515/therapie/2011014. Epub 2011 Jun 6.
4
Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
Clin Exp Dermatol. 2010 Oct;35(7):795-6. doi: 10.1111/j.1365-2230.2010.03829.x.
5
Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders.
Expert Rev Clin Immunol. 2009 Jul;5(4):421-31. doi: 10.1586/eci.09.18.
6
Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
Dermatology. 2010;220(3):234-7. doi: 10.1159/000275676. Epub 2010 Feb 20.
7
Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Dermatology. 2009;219(1):59-62. doi: 10.1159/000221005. Epub 2009 May 25.
8
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.
Ther Clin Risk Manag. 2008 Dec;4(6):1305-13. doi: 10.2147/tcrm.s967.
9
Ulcerative cutaneous sarcoidosis responding to adalimumab.
J Am Acad Dermatol. 2005 Nov;53(5):917. doi: 10.1016/j.jaad.2005.02.023.
Zotero 插件